CA2005358A1 - Somatotropin analogs - Google Patents
Somatotropin analogsInfo
- Publication number
- CA2005358A1 CA2005358A1 CA002005358A CA2005358A CA2005358A1 CA 2005358 A1 CA2005358 A1 CA 2005358A1 CA 002005358 A CA002005358 A CA 002005358A CA 2005358 A CA2005358 A CA 2005358A CA 2005358 A1 CA2005358 A1 CA 2005358A1
- Authority
- CA
- Canada
- Prior art keywords
- rbst
- somatotropin
- animal
- serine
- asparagine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/61—Growth hormones [GH] (Somatotropin)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
Abstract
SOMATOTROPIN ANALOGS
ABSTRACT
The present invention provides analogs of mammalian somatotropins wherein the asparagine residue of position 99 of the native mammalian somatotropin is replaced with a compound selected from the group consisting of proline, aspartic acid, glutamic acid, serine, glycine, serine-serine or serine-aspartic acid.
ABSTRACT
The present invention provides analogs of mammalian somatotropins wherein the asparagine residue of position 99 of the native mammalian somatotropin is replaced with a compound selected from the group consisting of proline, aspartic acid, glutamic acid, serine, glycine, serine-serine or serine-aspartic acid.
Description
3'~8 SOMATOTROPIN ANALOGS
FIELD OF INVENTION
This invention relates to analogs of animal somatotropins or growth hormones. More specifLcally, the invention relates to novel bovine growth hormone analogs, particularly with changes in amino acid residue 99.
BACKGROUND OF THE INVENTION
Bovine somatotropin (bSt) ls a growth hormone that has been well studied (Paladini, A.C. et al., CRC Crit. ~ev. Biochem. 15:25-56 (1983)). Somatotropins were originally discovered in pituitary gland extracts from various animals. In general, somatotropins are conserved molecules and similarities in amino acid sequences and structure are found between different species of animals.
Somatostatins, including bSt, are globular proteins comprising a single chain of about 200 amlno acids with two intramolecular disulfide bonds. Specifically, bSt has a single 190-191 amino acid chain, a globular structure with two intramolecular disulfide bonds and a molecular weight of about 22,000 daltons.
Natural bSt extracted from pituitary glands is heterogeneous.
At least six major forms of the protein have been described. The longest form has 191 amino acid residues and an ala-phe amino terminus. The second form has 190 amino acid residues and a phe amino terminus. The third form has 187 amino acid residues and a met amino terminus. The remaining three forms of bSt substitute valine for leucine at position 127. In additlon to this heterogeneity, undefined heterogeneity of bovine somatotropin has also been describ-ed ~Hart, I.C. et al., Biochem. J. 218:573-581 (19843; Wallace, M. and Dickson, H.B.F., Biochem. J. 100:593-600 (1965)).
Undefined electrophoretic heterogeneity i.s seen when the n~ltlve extracts are fractionated by anlon oxeharlge chroma~ography. It has been shown that the de~ined forms have diEeront relative potency in bioassays. Also, it has been shown that other undefined species of bSt when fractionated on ion exchange columns demonstrate varying degrees of bioactivity in rat growth models (Hart, et al. and Wallace and Dickson, supra).
It is not known whether undefined heterogeneity exhibiting biological variation is due to genetic variability, to in vivo post-translational modification, to differences in phosphorylation 3'~8 (Liberti, J.P. et al., Biocheln. and Biophys. Res. Comm, 128:713-720, 1985), or to artifacts of isolation.
Bovine somatotropin produced by recombinant microorganisms (rbSt), or extracted from pituitary gland tissue, ls important commercially. It increases lacta~ion in dairy cattle and increases size and meat production in beef cattle. It is estimated that upwards to 20 mg per animal per day will be needed to effect commer-cially acceptable improvements in production. Such a dosage will require efficient methods of administration. Improvements in the potency and stability of bSt such as described in this invention will be of benefit because of resulting reductions in the amount of drug administered to each animal per day.
Furthermore, one of the problems in preparing recombinantly-produced bSt is that liquid processing and storage of rbSt at ac.id or alkaline pH results in the conversion of the asparagi.ne residue at position 99 to isoaspartic acid. The resulting rbSt is referred to as "early eluting rbSt" because it elutes earlier than native rbSt on reversed phase HPLC. Isoaspartate is formed when the asparagine side chain condenses with the peptide backbone resulting in the elimina-tion of ammonia. Chain cleavage also occurs by a condensationreaction between the peptide backbone and the asparagine residue at position 99 of the rbSt molecule upon storage. The chain-cleaved product is covalently held together by the disulfide bond between cysteine residues 53 and 164 and has been called "early-early eluting rbSt" because of its eluting position relative to native and early eluting rbSt.
Because the instability that occurs due to the modification of asparagine 99 leads to a loss of native rbSt during its isolation, formulation and storage as reconstituted product, :Lt would be advantageous to make an amino lcid substltutlon at: posl.tion 99 to produce an rbSt nnl10g that is more stable while retaining or enhancing i.ts biological activity.
INFORMATION DISCLOSURE
Analogs of bSt are known (see, for exa~ple, Europem patent applications 75,444 and 103,395 and Nucleic Aci.d Res. 10(20):6487 (1982)).
G. Winter and A.R. Fersht, TIBS, 2, p. 115 (1984) review the alteration of enzyme activity by changing amino acid composition at ;~ ~3 ~
key sequence locations.
P.Y. Chou and G.D. Fasman, Ann. ~cev. Biochem., 47, pp. 251-76 (1978~ refer to the use of amino acid sequences to predict the secondary and tertiary structure of proteins. P.Y. Chou and G.D.
Fasman, J. Mol. Biol., 115, pp. 135-75 (1977) refer to ~-turns in proteins. From analysis of 459 ~-turn regions in 29 proteins of known sequence and X-ray structure, they found that the most frequently occurring amino acids in the third position of a ~-turn are asparagine, aspartic acid, and glycine. The residues with the highest ~-turn potential in all positions within the turn are proline, glycine, asparagine, aspartic acid, and serine.
SUMMARY OF THE INVENTION
This invention relates to the enhancement of bioactivity or stability in liquid storage, or both, of bSt and analogs thereof, by substituting different amino acids for the asparagine corresponding to the residue at position 99 of native bSt. Similar changes can be made in somatotropins from other animals, particularly mammals, including porcine, fish, ovine, horse, rat, monkey, and human.
More specifically, and preferred, are those species of bSt-like compounds wherein the asparagine located at amino acid residue 99 is replaced with a different amino acid residue including specifically glycine, serine, proline, aspartic acid, glutamic acid, serine-serine or serine-aspartic acid.
More specifically, the animal somatotropin is selected from the group consisting of bovine, porcine, fish, ovine, horse, rat, monkey, and human somatotroplns.
Even more specifically, the animal somatotropin is bovine somatotropin.
Also provided is a method for enhancing the growtll of an animal, particularly a mnmmal, Ancl more pMrtl.cularly a bov;Lne, which com-prises administering to the anLIlla:L an eectiv~ amount of n somato-tropin of the instant invention, and, in particular, where the animal is a bovine and the somatotropin is bSt.
Also provided is a method for increasing milk production in a fema].e ruminant comprising administering to the female ruminant an effective amount of an animal somatotropin of the instant invention, and, in particular, where the animal is a bovine and the somatotropin is bSt.
DETAILE~ DESC~IPTION
Due to the molecular heterogeneity of somatotropins, the position numbers of amino acid residues of the various somatotropins may differ. The term "native mammalian somatotropin" includes these naturally occurring species. Chart 1 illustrates the specific region of one species of bSt that corresponds to the position 99 residue modified by this invention. The numbering for other somatotropins may differ where other species or analogs are involved. Using the asparagine 99 of the bSt set forth in Chart 1, those of ordinary skill in the art can readily locate corresponding amino acids in alternative animal somatotropins, for example, mam~alian somatotro-pins, for e~ample, asparagine 99 of mammalian somatotropin, or their analogs, to achieve the desired liquid storage stability, enhanced bioactivity and uniform potency of the instant invention.
Both chemical and genetic modifications of this region are embraced by this invention.
The preferred genetic modifications rely upon single site specific mutation methods for insertion of various amino acid residues in replacement of the naturally occurring asparagine.
The phrase "animal somatotropin" refers to somatotropins originating from animals, e.g., mammals, and includes somatotropins derived from either natural sources, e.g., pituitary gland tissue or from microorganisms transformed by recombinant genetics to produce a naturally-occurring form of somatotropin. When a specific mammalian source is named such as a bovine somatotropin or a somatotropin of bovine origin, the somatotropin includes those derived from either natural sources or from transformed microorganisms.
The term "microorganism" is used herein to include both single cellular prokaryotic and euknryotic organisms such ag b~ct0rin, yeast, actinomycetes and singl0 c~ rom higher plants nnd animals grown in cell culture.
The term "native" refers to naturally-occurring forms of somatotropins which may have been derived from eLther natural sources, e.g., pitultary gland tissue or from mlcroorganisms trans-formed by recombinant genetics to produce a somatotropin having thesame amino acid sequence as the naturally-occurring form of somato-tropin.
The mammalian somatotropins are very similar in amino acid ~0'i3'~8 -s-sequence and physical structure. Although the processes described in the Examples are directed toward bSt, the processes are sgually applicable to any animal, e.g., mammalian somatotropin having the requisite asparagine residue available for replacement particularly wherein similar liquid processing and storage problems are en-countered.
The high relative potency of the bSt analogs of the present invention is readily determlned using hypophysectomized rats. Evans, H.M. and Long J.A., Anat. Rec. 21:61, 1921. Relative increases in 1.0 total body weight are recorded using pituitary bSt, recombinant bSt (rbSt) and various bSt analogs of the invention.
Site-Directed Mutagenesis: Several techniques for site-directed mutagenesis have been developed for introducing specific changes in a DNA sequence and may be used to produce the compounds of the instant invention (Kramer, W., et al, Nucl. Acids Res., 12, pp. 9441-56 (1984); Mandecki, W., Proc. Natl. Acad. Sci. USA, 83, pp. 7177-81 (1986); Zoller, M.J. and Smith, M., Nucl. Acids Res., 10, pp. 6487-6500 (1982); Norrander, J., et. al., Gene, 26, pp. 101-106 (1983);
Kunkel, T.A., Proc. Natl. Acad. Sci. ~SA, 82, pp. 488-92 (1985);
Schold, A., et. al., DNA, 3, pp. 469-77 (1984)). We employed the primer directed mutagenesis technique of Schold et al for five of the seven analogs produced, except that only one primer is used for the initial hybridi.zation reaction and 18 ~1 of T4 gene 32 protein is added to the extension reaction.
Colony Filter Hybridization: The screening technique of filter hybridization is based upon the ability of a single-stranded segment of DNA to locate its complementary sequence and hybrldize to form a double-stranded segment, Hanahan, D. and Meselson, M., Meth. En-zymol., 100, pp. 333-42 (1983). The therlllnl stnbility oE this binding is dependent upon the nulllber oE mntches ~nd mismatches contained within the double stranded region. The more mismatches it contains, the weaker the base-pair bi.nding and the lower the tempera-ture necessary to disrupt the DNA binding. This temperature dif-ferential is exploited during colony fi.lter hybridizati.on, Bryan, R., et. al., Microbiology (1986). By constructing a mutant oligomer which maximizes the temperature differential between the native and mutant sequence, it is possible to hybridize at a lower temperature allowing binding of the probe to matched and nearly matched sequen-0 13 ~ ~ 8 ces. Upon w~shing at elevated t~mperatures, the mismatched probe-DNA
duplex beco~es unstable and disassociates while the perfectly matched duplex remains bound. The matched duplex will then produce the darkest signaL on an autoradiogram thus forming a detection method for a colony containing the desired sequence. DNA from this colony can then be isolated and sequenced.
For filter preparation, nitrocellulose filters are overlayed onto plates and wetted. The filters and plateq are ~arked for orientation and the filters are then carefully lifted off the plates.
The master filter plates are incubated overnight at room temperature to allow re-growth of the colonies. The filters are denatured by laying them one by one onto Whatman paper soaked in 0.5 M NaOH, 1.5 M
NaCl for 10 minutes and neutralized in two successive changes of Whatman paper soaked in 1 M Tris, pH 7.4, 1.5 M NaCl, for 10 minutes each and air dried on fresh Whatman paper for 30 minutes. They are then baked for 2 hours at 80C in vacuum.
The kinase reaction to radiolabel the mutant oligonucleotide for use as a probe is as follows: 2 ~g of oligo, 2 ~1 of lOX kinase buffer, 100 ~Cl ~32-P ATP, 2 ~1 T4 kinase and 4 ~1 water are mixed and incubated for 1 hour at 37C. A 1 ml column is packed with DEAE-Sephacel in a 10 ml disposable column and equilibrated with 2-3 ml of high salt buffer (1.5M NaCl in TE) and then 2-3 ml of low salt buffer (0.2M NaCl in TE). The kinase reaction is diluted with 200 ~1 of low salt buffer and loaded directly into the column. The column is washed with 10 ml of low salt buffer until no further counts elute from the column. The probe is eluted in 4 ml of high salt buffer.
To hybridize, the filters are placed in a crystallization dish and batch pre-hybridized in 5X Denhardts (1% BSA, 1% Ficoll and 1%
PVP), 5X SSC (0.75 M NAC1, 0.075 M sodiwn cltrate) and 0,1~ SDS for 1 hour at 40C. The hybridiz~tlon solution is ch~lnged ~nd the probo is added. The dish is covered and the hybridizstion done overnight with gentle agitation. The filters are then rinsed wlth several changes of 5X SSC, 0.1% SDS. The filters sit in this solution while the water bath and wash solution (5X SSC, 0.1% SDS) is heated up to washlng temperature (46C). The filters are transferred one by one to a fresh crystallization dish and washed 3 x 20 minutes, changing dishes after each wash. They are then air dried on Whatman paper, wrapped in Saran wrap and exposed as necessary.
;~Q~rJ~t38 Vector DNA Preparatlon: GNA for sequencin~ is obtained accord-ing to the method of L. Agellon and T. Chen, Gene Anal. Techn., 3, pp. 86-89 (1985) except that only one combined phenol/chloroform extraction ls performed and the DNA is not spin-dialy~ed through a Sephadex G-50 column.
Sequencing: Double-stranded sequencing is performed accordln~
to the following protocol: 3 ~1 2N NaOH, 2 mM EDTA is added to 12 ~1 of DNA (2 ~g) and incubated for 15 minutes. 6 ~1 3 M NaOAc, 1 ~1 primer and 100 ~1 95~ ethanol are added and the DNA precipitated on dry ice for 20-30 minuees~ The pellet is collected, washed and vacuum dried. It Ls dissolved in 13 ~1 water and 4 ~1 RT buffer (0.3 M Tris-HCl, pH 8.3, 0.375 M NaCl, 37.5 mM MgC12, 2.5 mM DTT), 2 ~1 ~32P dCTP and 1 ~1 reverse transcriptase are added. 4 ~1 of this mi~
is pipetted into 4 eppendorf tubes, each contalning 1 ~1 of G mix, A
mix, T mix or C mix. The tubes are incubated for 10 minutes at 42~C.
1 ~1 of chase mix (0.25 mM dNTPs) is added and they are incubated for an additlonal 5 minutes. 10 ~1 stop solution (80~ formamide, 10 mM
NaOH, 1 mM EDTA, 0.1% xylene cyanol and 0.1~ bromphenol blue~ is added, the reactions are boiled 3 minutes and 3 ~1 of each is loaded onto a sequencing gel.
Induction Protocol and SDS-PAGE Analysis: See PCT/VS 88/00328.
Example 1 A site-directed mutagenic technique for double-stranded primer extension is u.sed to introduce altered codons for serine and proline at amino acid position 99 in the rbSt cDNA m4 gene (PCT patent application PCT/US 88/00328, filed 27 January 1988 and incorporated herein by reference). In this method, the target sequence is cloned into a suitable plasmid and plasmid DNA is prepared. The plaslnid DNA
is denatured by treatment with NaOH whi~h causes "nicks" in the DNA
molecule deoxyribose-phosph~lte baGkbon~. 'rhis relax~s the DNA and permits an oli~omer containing tho deslred sequence chan~es to hybridize to the plasmld sequence containing the position 99 residue of bSt. The 3' end of the oligomer generates a prime.r Eor the DNA
polymerase activity of the reverse transcriptase which extends the primer, synthesizes a new DNA strand containing the mutagenic oli~omer and displaces the normal complementary strand. The exten-sion reaction increases the probability of the incorporation of the oligomer-directed change. The DNA is transformed into competent ;~o~
cells and the resultant colonies are screened by colony filter hybridization. Plasmid DNA ls isolsted and sequenced from positive candidates.
The oligomers used to construct the position 99 serine and proline changes in the rbSt m4 gene are produced by techniques previously described (PCT/US 88/00328), An oligonucleotide so produced and designated GST-88 (Chart 3) contains the change on the DNA sequence asparagine AAC to serine TCT and another designated CST-89 (Chart 3) contains the asparagine AAC to proline CCG change. They are both designed with a Tm of 53C thus allowing for hybridization at 40C and stringent washing at 46C as set forth above.
In parallel experiments the serine and proline oligomers are hybridized to the pBR322 derived vector pTrp-BStm4, This vector contains the trp promoter and the m4 cDNA for rbSt (PCT/US 88/00328), After primer extension, the DNA is used to transform competent cells of MC1000 (available in the Experiments with Gene Fusion Strain Kit, Cold Spring Harbor Laboratory, Cold Spring Harbor, New York). The transformed cells are plated to give 100-200 colonies on ten plates.
The colonies are then transferred onto nitrocellulose, The cells are lysed and their DNA affixed to the filter, Radiolabeled oligomer probes are prepared from CST-88 and CST-89 by the oligomers with kinase and 32P-ATP. Details of the colony filter hybridization probing are set forth above, Six candidates gave a very strong positive signal on the autoradiogram for the serine mutagenesis, Plasmid DNA was isolated for each candiclate and sequenced, One of the candidates was found to contain the serine change, The mutated gene contained therein is designated m4-99ser. For the proline mutagenesis, six positive candidates were analyz,ed by DNA sequencing and two were found to contain the desired change. These mutated genes ~ro clcsignflted m4-99pro.
The m4~99ser and m4-99pro genes are excised from the parental vector as an EcoRI-HindIII fragment and cloned into the EcoRI-HindIII
restriction sites of the pURA-m4 vector (PCT/US 88/00328). Chart 2 shows the cloning of the m4-99ser gene into the pURA-m4 vector, The identiccal construction is carried Otlt for the m4-99pro gene. Upon sequence confirmation of the clonings, the vectors are designated pURA-99Ser and pURA-99Pro. These vectors are transformed into 3'i8 fermentation expression strain BST-lC (P~T/~S 88/00328).
Transformed cells from each of the clonings are induced and samples analyzed by SDS-PAGE to assess the ability of the cells to express the modified rbSt genes under non-optimized conditions Results of SDS-PAGE analy~is showed that pURA-99Ser produced rbSt in three indlvidual inductions at 13.8%, 14.6~ and 26.4% of total cellular protein. Results of SDS-PAGE analysis showed pURA-99Pro in four separate inductions expressed rbSt at 28.2%, 29.6~, 34.0~ and 41.9% of total cellular protein.
Because of poor mutagenic efficiency, the mutant oligomer must be constructed so that there is at least a 5~C temperature difference between its Tm and that o~ the native sequence. Witho~lt this difference, effective screening of the candidates cannot be ac-complished.
Example 2 Following the techniques of Example 1, but substituting the appropriate oligomers encoding the desired amino acids (C-ST 90 and C-ST 91, Chart 3), bSt analogs having aspartic acid and glutamic acid at position 99 were also constructed.
Example 3 Analogs having two amino acids substituted in place of the position 99 asparagine (Ser-Ser and Ser-Asp) were constructed by fol-lowing the site~ directed protocol of Kramer et al, Nucl. Acids Res., 12, p. 9441-56 (1984) as described in the "Site Directed Mutagenesis Kit", commercially available from Boehringer Mannheim Biochemicals, P0 Box 50816, Indianapolis, IN 46250 (see also, Kramer, W. and H-J
Fritz, Meth. Enz., 154, pp. 350-67 (1987)). The procedure requires cloning the DNA sequence which is to be modified into the M13mp9 vector. This is done by digesti.ng vector pURA-m4 (PCT/US 88/00328) with the restriction enzymes EcoRI arld BamtlI and Lsol1~1n~ 1 DNA
fragment approximately 870 bp ln .s i.z~ . 'I'his Eragment con~ains tlle E .
coli tryptophan (trp) promoter, ttle trpL rlbosome blnding site an~
the entire bSt gene sequence. This fragment is cloned into the EcoRI
and BamHI restriction sites of the M13mp9 vector using known techni-ques (Maniatis et al, Molecular Cloning: A Laboratory Manu~l, ColdSpring Harbor Publication, Cold Spring Harbor, New York; J. Messing, Meth. En~ym., 101, pp. 20-98 (1983)). Single stranded DNA is isolated using the derived vector M13mp9-m4 (Messing, supra) and used 3 rj 8 in the mutagenesis procedure as previously descrlbed. Cloning of these analogs into the pURA expression vector was done as described in Exa~.ple 1, in which ~he double-stranded DNA of the M13 vector, supra, is substituted for the pBR322 vector Example 4 A position 99 analog having glycine substituted for asparagine was also constructed using the techniques described in Example 1.
The mutagenesis oligonucleotide used is designated C-ST84 (Chart 3).
It encodes the change to glycine.
Example 5 Activity of various position 99 analogs was demonstrated. The parameter measured was to estimate differences in 3.5~ fat corrected milk yield (FCM) of lactating dairy cows in~ected intramuscularly with native rbSt, the glycine-99 (Gly-99) rbSt of Example 4, the serine-99 (Ser-99) rbSt of Example 1 and the aspartic acid-99 (Asp-99) rbSt of Example 2. Holstein cows (45) were ranked from high to low milk yield based on milk yield on days 3 and 2 prior to initia-tion of rbSt injections. The cows were assigned randomly in repli-cates, based upon milk yield, to 9 experimental groups: no injection (Control), 5 mg and 20 mg Gly-99 rbSt daily, 5 mg and 20 mg Ser-99 rbSt daily, 5 mg and 20 mg Asp-99 rbSt daily, and 5 mg and 20 mg native rbSt daily. Cows were in;ected imtramuscularly in the semitendinosus muscle once daily for 21 days. Twice daily milk weights were recorded for three days prior to initiation of injec-tion, during the 21 days of injections, and for fi.ve days after the last in~ection. Concentration of rbSt was expected to be 10 mg/ml.
The concentration of residual post-injection rbSt solutions, measured by HPLC, averaged 11.5 for native rbSt, 12.1 for Asp-99 rbSt, 11.6 for Gly-99 rbSt, and 11.6 for Ser-99 rbSt. The area percent was greater than 99~ normal rbSt for Gly-99 rbSt (by "norm~l rbSt" is meant the amino Mcid s~cluenco Qncoded by ~ particular gene, i.e., no degrad~tion products, otc.), for Ser-99 rbSt, and for Asp-99 rbSt, but averaged 90.5 normal rbSt for native rbSt. Native rbSt averaged 2~ early-early eluting rbSt and 7.6~ early eluting rbSt.
Statistical analyses of the FCM among experimental groups were based on average FCM for days 1 to 21 of in~ections using the three days prior to initiation of injections as the covariate. Average daily FCM (kg/day) was not statistically significantly different for either form of rbSt (Y<.12) or dose X form o~ rbSt interaction (P<.90). However, since the statistical signlficance was P<.12 for form of rbSt, an attempt was made to gain additional information on the relative potency among the forms of rbSt. Based on comparisons among the four forms of rbSt, there was a suggestion (P<.05) that FCM
of cows injected with Ser-99 rbSt was grea~er than FCM for cows injected with eLther Gly-99 rbSt or native rbst. There was no suggestion of a difference in FCM of cows injected with Ser-99 rbSt compared to cows injected with Asp-99 rbSt or among cows injected with Gly-99 rbSt, Asp-99 rbSt, and native rbSt. FCM of cows adminis-tered 20 mg rbSt was statist;cally significantly greater than cows administered 5 mg.
Experimental Mean FCM Relative to Changea Percentage 15 GroupDays of Injection(kg/day) Change for Days pre durlng post duringa postb Control 27.6 26.1 26.1 -1.5 -5.4 0 Native 5 mg 28.2 28.0 26.8 -0.2 -0.7 -4.3 Native 20 mg 26.6 30.2 26.0 3.6 13.5 -13.5 Asp-99 5 mg 28.1 29.2 29.2 1.1 3.9 0 Asp-99 20 mg 24.5 29.0 27.0 4.5 18.4 -6.9 Gly-99 5 mg 29.3 29.4 17.2 0.1 0.3 -7.5 Gly-99 20 mg 26.4 29.8 28.6 3.4 12.9 -4.2 Ser-99 5 mg 28.8 31.0 30.4 2.2 7.6 -1.9 Ser-99 20 mg 28.9 33.5 31.6 4.6 15.9 -5.7 aDays 1 to 21 o injectlon relatlve to days 1 to 3 pre-in~oction.
bDays 1 to 5 post-ln~ectl.oll r~lntlvo to dsys 1 to 21 of lnJection.
F.x~mple 6 Activity oE other position 99 analogs was demonstrated in a separate study from that reported in Example 5. Again, the param~ter measured was to estimate differences in 3.5% fat corrected milk yield (FCM) of lactatlng dairy cows injected intramuscularly with native rbSt (clinical rbSt) that has asparagine at position 99, rbSt with proline substituted for asparaglne at posltion 99 (Pro-99 rbSt), and ~r~r~
rbSt with glutamic acid substituted for asparagine at position 99 (Glu-99 rbSt). Holstein cows ~35) were ranked from high to low milk yield based on milk yield on days 3 and 2 prior to initlation of rbSt injections. The cows were assigned randomly in replicates, based upon mllk yield, to 7 experimental groups: no injection (Control), 5 mg and 15 mg Pro-99 rbSt daily, 5 mg and 15 mg Glu-99 rbSt daily, and 5 mg and 15 mg native rbSt daily. Cows were injected imtramuscularly in the semitendinosus muscle once daily for 7 days. Twice daily m~lk weights were recorded for three days prior to initiation of injec-tion, during the 7 days of injections, and for five days after thelast injection.
The dose averaged 5.04 mg, 4.88 mg, and 5.03 mg for cows assigned to receive the 5 mg dose of Pro-99, Glu-99, and native rbSt respectively. Cows assigned to receive 15 mg rbSt received 15.12 mg, 14.64 mg, and 15.10 mg rbSt for cows of the Pro-99, Glu-99, and native rbSt respectively. The percentage of early-early eluting rbSt, early eluting rbSt, oxidized rbSt, and post-oxidized rbSt appeared to be similar for native rbSt, Glu-99 rbSt, and Pro-99 rbSt.
Statistical ana].yses of the FCM among Experimental Groups were based upon average FCM for days 1 to 7 of injections using the three days prior to initiation of injections as the covariate. The FCM for cows of the native rbSt, Pro-99 rbSt, and Glu-99 rbSt groups was 28.7, 28.8, and 28.8 (P .95). Therefore there was no suggestion of a difference of FCM for cows receiving nati~e rbSt, cows receiving rbSt with glutamic acid substituted for asparagine at position 99, and cows receiving rbSt with proline substituted for asparagine at position 99. FCM was significantly greater for cows of the 15 mg rbSt group than for cows of the 5 mg rbSt group. Upon cessation of rbSt in~ections, FCM of rbSt previously inJocted cows d~creased at similar rates during the 5 days after cessAtion of rbSt in~ections.
Rxample 7 Samples of rbSt and rbSt position 99 analogs were examined for relative potency using the hypophysectomized rat growth bioassay.
Two hundred hypophysectomized fema].e Sprague Dawley rats weighing between 75 and 150 grams were used in each experiment. They were fed pelleted Purina Rat Chow ad libitum and watered with deionized and rechlorinated water. Room conditions were set at a temperature of 80 F and relative humidity of 50%. Air exchange was approximately ;~0~;3'~
20 exchanges per hour and the photoperiod was 12 hours light nnd 12 hours dark, with the light cycle commencing about 6:00 a.m.
The rats were monitored for a 12-day prelimlnary period to allow for adaptation to environmental and feeding conditions. Body weights were obtained on four occasions between days one and twelve. Rats that showed weight losses of one gram per day or less or weight gains of 2 grams per day or less during the preliminary period were selected for inJeCtion with rbSt. The rats were ranked according to ascending magnitude of average daily galn (ADG), and seven blocks of 25 rats were created. Treatments within each block were randomly assigned.
rbSe treatments lasted 10 days. During this time, test co~-pounds were injected twice daily for nine days, and body weights were monitored using a Mettler Model 3600 top loading balance equipped with lab-Pac programming which determines the weight of the animals while taking into account their movements.
Stock solutions of rbSt at 2 mg/ml were prepared in a buffer of 0.03 M sodium bicarbonate and 0.15 M NaCl at pH g.5. To facilitate suspension of rbSt, the ].yophilized preparations were first dissolved 20 in this buffer at pH 10.8, then the pH was adjusted to 9.5 using 2 N
HCl and brought to final volume using the stock buffer at pH 9.5 and filtered if necessary.
The stock solutions were diluted using stock bufEer (pH 9.5) to solutions of 37.5, 75, 150, and 300 mg of protein/ml. The rats were injected subcutaneously twice daily with 100 ~1 of the respective solutions, and controls received 100 ~1 of buffer. The experiment lasted 10 days with average daily weight gain monitored.
A statistical analysis of the relative potency for the various test samples of rbSt was as follows: native rbSt with asparagine at position 99 served as an analytical st~ndard and wns nssigned relative potency vAlue o~ 1.00. 'I'hi.s sampl.c had a potency of 1.15 relative to A snmple of pltuitnry-tlerlved bovinc somatotropin. The rbSt analogs in which aspartlc ncid, glutamic acid, glycine, proline, serine, and serine-serine were substituted for the asparagine at 35 position 99, had relative potencies (respecti.vely) of 2.30, 3.00, 2.96, 2.50, 3.06, and 3.03 relative to rbSt control. These values are significant at the 95~ confldence level.
;~C~ ~3'~
Example 8 The aqueous stabilities of three of the rbSt position 99 analogs, having glycine, serine, and aspartic acid substituted for asparagine, were compared wlth that of native (asparagine at 99) rbSt under two sets of incubation conditions. The first set of incuba-tions was carried out in 50 mM sodium carbonate, pH 10.0 at ambient temperature (protein concentration 20 mg/ml) to simulate conditions similar to those encountered during the isolation and formulation of rbSt. The second set of incubations was carried out in a pH 7.4 Ringer's solution at 37C (protein concentration 5 mg/ml) to simulate exposure to physiological conditions. All incubation samples were prepared aseptically. Samples were removed from the incubations over a three week period and stored at -20C prior to analysis by iso-electric focusing, SDS-PAGE, and reversed phase HPLC.
The glycine 99 and serine 99 rbSt analogs had IEF patterns that were virtually indistinguishable from native rbSt prior to incubation while the IEF pattern of native asparagine 99 rbSt was shifted approximately 1.2 pH units lower due to the introduction of the negative charge at position 99. The major difference noted between the IEF patterns of incubated samples of native rbSt and the position 99 analogs was the rate at which more acidic rbSt species were formed. The IEF pattern of native rbSt degraded into more acidic rbSt spe~ies at a faster rate under both sets of incubation condi-tions than did the IEF patterns of the position 99 analogs. One additional difference between the IEF patterns of native rbSt and the analogs was the presence in incubated native rbSt samples of IEF
bands that have been associated with a chain cleavage between residues 99 and 100 of the rbSt molecule. These bands were not observed in the IEF patterns of the position 99 analog~.
~en analyzed under non-reducln~ conditlons, the SDS PACE
behavior of incubat~d samples of the posLtion 99 analog~ was identi-cal to that of native rbSt. When examined under reducing conditions, however, the major rbSt fragment formed during the incubation of native rbSt was found to be absent in the position 99 analogs.
Replacement of the asparagine residue at position 99 with either glycine, serine, or aspartic acid therefore eliminated the peptide bond cleavage between residues 99 and 100. The two peptides formed as a result of this cleavage in native rbSt are normally held - 1 s -covalently intact by the disulfide bond between cysteine residues 53 and 164, thus the difference between the reduced and non-reduced s~mples.
Reversed phase HPLC was used to measure the amount of isoaspar-tate formation and chain cleavage which occurred at position 99 of the rbSt molecule since these species elute earlier upon reversed phase ~IPLC than native rbSt. rbSt which contained a chain cleavage between positions 99 and 100 of the rbSt molecule accounted for 8.5 area percent of native rbSt at the conelusion of the pH 10.0 incuba-tion, and for 11.1 area pereent of native rbSt at the conelusion ofthe pH 7.4 incubation. By comparison, the amount of the rbSt analogs which eluted in this position was less than 0.5 area percent. rbSt which eluted in the position of isoaspartic acid 99 rbSt accounted for 35.8 area percent of native rbSt at the conclusion of the pH 10.0 incubation, and for 49.9 area percent of native rbSt at the con-clusion of the pH 7.4 incubation. Of the position 99 rbSt analogs, aspartic acid 99 rbSt showed the greatest formation of rbSt which eluted in this position: 3.8 area percent at the conclusion of the p~I 10.0 incubation and 13.9 area percent at the conclusion of the pH
7.4 incubation.
Therefore, the position 99 analogs of the instant invention show superior aqueous stability relative to native asparagine 99 rbSt.
Example 9 Following the teachings of the preceding examples with ap-propriate modifications, similar analogs to porcine, human, ovine,horse, rat, monkey and avian somatotropins may also be produced by replacing the asparagine residues at position 99 (S.S. Abdel-Meguid, et al, Proc. Natl. Aead. Sci.. USA, 84, pp. 6434-37 (1987). Because of the close sequence homology botween mclmmall~ oln~Itotropins in this region of the molec-I].e, tIle a~IpclrclgLlle residue corre.sponding to bSt asparagine 99 is likely tho third residue in a ~-turn in eaeh of these other somatotropins thus leading to isoaspartic acid formakion and chain cleavage as with bSt. If this is Eound to be the case for other somatotropins by analysis of the products as set forth above, substituting an appropriate amino aeid for the asparagine 99 would obviate the isoaspartate formation and chain cleavage.
Administration of the bSt analogs into dairy cattle is according to known methods using any route effective to deliver the required 2Q~ 3 ~
dosage to the animal's circulatory system. Modes of administration include oral, intramuscular in~ections, subcutaneous in3ectlons and the use of timed-release implants. The preferred mode of administra-tion is by subcutaneous in~ection using a timed-release implant.
Appropriate vehicles for injections include physiologically com-patible buffers such as sodium bicarbonate, sodi~m phosphate, or ammonium phosphate solutions. Timed-release implants are known in the art, e.g., U.S. patent 4,333,919.
The effective dosage range is from 1.0 to 200 milligrams per animal per day. The greater the amount of bSt given, the greater the resulting increase in growth, lactation or numbers of mammary parenchymal cells. Most preferably, the dosage range is from 5 to 50 milligrams per day.
Mammalian growth hormones are very similar in their amino acid sequences and hormones originating from one animal source can enhance the growth of other unrelated species of animals. For purposes of increasing growth rate of animals, the analogs of the present invention can be used to produce increased growth in the same animal species in which native bSt has been shown to have growth-related bioactivity such as bovines, sheep, rats, salmon and chickens. The preferred animals are bovine used for beef cattle such as bulls, heifers or steers.
Beef cattle are slaughtered ~ust prior to reaching full maturity and size. The bSt analogs of the instant invention can be used to produce increased growth rates in beef cattle by administration any time between weaning until slaughter. The bSt are administered to beef cattle for a minimum of 30 days and for a maximum of 450 days depending upon desired time of slaughter. Animals used for veal are typically slaughtered at approximately 6 months of age and 10 to 30 mg/day of the bSt Dnalog is admini~tered up until the n~o of slaugh-ter to effectuate desired lncreasos in growth rate.
For purposes of increasing lactstion in bovines, particularly dairy cows, the bSt analog is administered between 30 and 90 days postpartum and continued for up to 300 days. The bSt analog will also increase lactation in other commercial milk-producing animals such as goats and sheep.
.
2~ 3'~8 CHART 1. Amino Acid Sequence Of Bovine Somatotropin ala phe pro ala met ser leu ser gly leu phe ala asn ala val leu arg ala gln his leu his gln leu ala ala asp thr phe lys glu phe glu arg thr tyr ile pro glu gly gln arg tyr ser ile gln asn thr gln val ala phe cys phe ser glu thr ile pro ala pro thr gly lys asn glu ala gln gln lys ser asp leu glu leu leu arg ile ser leu leu leu ile gln ser trp leu gly pro leu 25 gln phe leu ser arg val phe thr asn ser leu val phe gly thr ser asp arg val tyr glu lys leu lys asp leu glu glu gly ile leu ala leu met arg glu leu glu asp gly thr pro arg ala gly gln ile leu lys gln thr tyr asp lys phe asp thr asn met arg ser asp asp ala leu leu lys asn tyr gly leu leu ser cys phe arg ly9 asp leu his lys thr glu thr tyr lou srg v~l m~t lys cys arg arg phe gly glu ala ser cys ala phe CH~RT 2. Clonlng of the m4-99ser gene lnto the pURA Vector 1) A plasmid contalning the m4-99ser gene ls digested with EcoRI and HindIII to produce Fragment 1.
5EcoRI HindIII
BBBBBBBBBBBBBBBBB ¦ ~--------------ori Ampr Fragment 1 EcoRI HindIII
BBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBB
2) Plasmid pURA-m4 is digested with EcoRI and HindIII to produce Fragment 2.
EcoRI HindIII
* I ,,__. l l l l I , cop cop rep ori ori Ampr Fragment 2 HindIII EcoRI
cop cop rep ori ori Ampr 3) Fragments 1 and 2 are then lignted togeth~r to protl~lc~
0 plnsmid pURA-99ser.
HindIII EcoRI
* ---~ I *
BBBBBBBBBBBBBBB
cop cop rep ori ori Ampr B ~ bSt m4-99ser gene ~05;~
CHART 3. Ollgonucleotides Used for Constructing rbSt Analogs C-ST 84 (gly) 5'-GTCTTCACCGGTAGCTTGGTG
C-ST 88 (ser) 5'-GTCTTCACCTCTAGCTTGGTG
C-ST 89 (pro) 5'-GTCTTCACCCCGAGCTTGGTG
C^ST 90 (asp) 5'-GAGTCTTCACTGATAGCTTGGTG
C-ST 91 (glu) 5'-GAGTCTTCACTGAAAGCTTGGTG
JM 23 (ser-ser) 5'- AGCAGAGTCTTCACCTCTTCCTCTTTGGTGTTTGGCACC
JM 57 (ser-asp) 5'-TCAGCAGAGTCTTCACCTCTGACTCCTTGGTGTTTGGCACCTCGG
FIELD OF INVENTION
This invention relates to analogs of animal somatotropins or growth hormones. More specifLcally, the invention relates to novel bovine growth hormone analogs, particularly with changes in amino acid residue 99.
BACKGROUND OF THE INVENTION
Bovine somatotropin (bSt) ls a growth hormone that has been well studied (Paladini, A.C. et al., CRC Crit. ~ev. Biochem. 15:25-56 (1983)). Somatotropins were originally discovered in pituitary gland extracts from various animals. In general, somatotropins are conserved molecules and similarities in amino acid sequences and structure are found between different species of animals.
Somatostatins, including bSt, are globular proteins comprising a single chain of about 200 amlno acids with two intramolecular disulfide bonds. Specifically, bSt has a single 190-191 amino acid chain, a globular structure with two intramolecular disulfide bonds and a molecular weight of about 22,000 daltons.
Natural bSt extracted from pituitary glands is heterogeneous.
At least six major forms of the protein have been described. The longest form has 191 amino acid residues and an ala-phe amino terminus. The second form has 190 amino acid residues and a phe amino terminus. The third form has 187 amino acid residues and a met amino terminus. The remaining three forms of bSt substitute valine for leucine at position 127. In additlon to this heterogeneity, undefined heterogeneity of bovine somatotropin has also been describ-ed ~Hart, I.C. et al., Biochem. J. 218:573-581 (19843; Wallace, M. and Dickson, H.B.F., Biochem. J. 100:593-600 (1965)).
Undefined electrophoretic heterogeneity i.s seen when the n~ltlve extracts are fractionated by anlon oxeharlge chroma~ography. It has been shown that the de~ined forms have diEeront relative potency in bioassays. Also, it has been shown that other undefined species of bSt when fractionated on ion exchange columns demonstrate varying degrees of bioactivity in rat growth models (Hart, et al. and Wallace and Dickson, supra).
It is not known whether undefined heterogeneity exhibiting biological variation is due to genetic variability, to in vivo post-translational modification, to differences in phosphorylation 3'~8 (Liberti, J.P. et al., Biocheln. and Biophys. Res. Comm, 128:713-720, 1985), or to artifacts of isolation.
Bovine somatotropin produced by recombinant microorganisms (rbSt), or extracted from pituitary gland tissue, ls important commercially. It increases lacta~ion in dairy cattle and increases size and meat production in beef cattle. It is estimated that upwards to 20 mg per animal per day will be needed to effect commer-cially acceptable improvements in production. Such a dosage will require efficient methods of administration. Improvements in the potency and stability of bSt such as described in this invention will be of benefit because of resulting reductions in the amount of drug administered to each animal per day.
Furthermore, one of the problems in preparing recombinantly-produced bSt is that liquid processing and storage of rbSt at ac.id or alkaline pH results in the conversion of the asparagi.ne residue at position 99 to isoaspartic acid. The resulting rbSt is referred to as "early eluting rbSt" because it elutes earlier than native rbSt on reversed phase HPLC. Isoaspartate is formed when the asparagine side chain condenses with the peptide backbone resulting in the elimina-tion of ammonia. Chain cleavage also occurs by a condensationreaction between the peptide backbone and the asparagine residue at position 99 of the rbSt molecule upon storage. The chain-cleaved product is covalently held together by the disulfide bond between cysteine residues 53 and 164 and has been called "early-early eluting rbSt" because of its eluting position relative to native and early eluting rbSt.
Because the instability that occurs due to the modification of asparagine 99 leads to a loss of native rbSt during its isolation, formulation and storage as reconstituted product, :Lt would be advantageous to make an amino lcid substltutlon at: posl.tion 99 to produce an rbSt nnl10g that is more stable while retaining or enhancing i.ts biological activity.
INFORMATION DISCLOSURE
Analogs of bSt are known (see, for exa~ple, Europem patent applications 75,444 and 103,395 and Nucleic Aci.d Res. 10(20):6487 (1982)).
G. Winter and A.R. Fersht, TIBS, 2, p. 115 (1984) review the alteration of enzyme activity by changing amino acid composition at ;~ ~3 ~
key sequence locations.
P.Y. Chou and G.D. Fasman, Ann. ~cev. Biochem., 47, pp. 251-76 (1978~ refer to the use of amino acid sequences to predict the secondary and tertiary structure of proteins. P.Y. Chou and G.D.
Fasman, J. Mol. Biol., 115, pp. 135-75 (1977) refer to ~-turns in proteins. From analysis of 459 ~-turn regions in 29 proteins of known sequence and X-ray structure, they found that the most frequently occurring amino acids in the third position of a ~-turn are asparagine, aspartic acid, and glycine. The residues with the highest ~-turn potential in all positions within the turn are proline, glycine, asparagine, aspartic acid, and serine.
SUMMARY OF THE INVENTION
This invention relates to the enhancement of bioactivity or stability in liquid storage, or both, of bSt and analogs thereof, by substituting different amino acids for the asparagine corresponding to the residue at position 99 of native bSt. Similar changes can be made in somatotropins from other animals, particularly mammals, including porcine, fish, ovine, horse, rat, monkey, and human.
More specifically, and preferred, are those species of bSt-like compounds wherein the asparagine located at amino acid residue 99 is replaced with a different amino acid residue including specifically glycine, serine, proline, aspartic acid, glutamic acid, serine-serine or serine-aspartic acid.
More specifically, the animal somatotropin is selected from the group consisting of bovine, porcine, fish, ovine, horse, rat, monkey, and human somatotroplns.
Even more specifically, the animal somatotropin is bovine somatotropin.
Also provided is a method for enhancing the growtll of an animal, particularly a mnmmal, Ancl more pMrtl.cularly a bov;Lne, which com-prises administering to the anLIlla:L an eectiv~ amount of n somato-tropin of the instant invention, and, in particular, where the animal is a bovine and the somatotropin is bSt.
Also provided is a method for increasing milk production in a fema].e ruminant comprising administering to the female ruminant an effective amount of an animal somatotropin of the instant invention, and, in particular, where the animal is a bovine and the somatotropin is bSt.
DETAILE~ DESC~IPTION
Due to the molecular heterogeneity of somatotropins, the position numbers of amino acid residues of the various somatotropins may differ. The term "native mammalian somatotropin" includes these naturally occurring species. Chart 1 illustrates the specific region of one species of bSt that corresponds to the position 99 residue modified by this invention. The numbering for other somatotropins may differ where other species or analogs are involved. Using the asparagine 99 of the bSt set forth in Chart 1, those of ordinary skill in the art can readily locate corresponding amino acids in alternative animal somatotropins, for example, mam~alian somatotro-pins, for e~ample, asparagine 99 of mammalian somatotropin, or their analogs, to achieve the desired liquid storage stability, enhanced bioactivity and uniform potency of the instant invention.
Both chemical and genetic modifications of this region are embraced by this invention.
The preferred genetic modifications rely upon single site specific mutation methods for insertion of various amino acid residues in replacement of the naturally occurring asparagine.
The phrase "animal somatotropin" refers to somatotropins originating from animals, e.g., mammals, and includes somatotropins derived from either natural sources, e.g., pituitary gland tissue or from microorganisms transformed by recombinant genetics to produce a naturally-occurring form of somatotropin. When a specific mammalian source is named such as a bovine somatotropin or a somatotropin of bovine origin, the somatotropin includes those derived from either natural sources or from transformed microorganisms.
The term "microorganism" is used herein to include both single cellular prokaryotic and euknryotic organisms such ag b~ct0rin, yeast, actinomycetes and singl0 c~ rom higher plants nnd animals grown in cell culture.
The term "native" refers to naturally-occurring forms of somatotropins which may have been derived from eLther natural sources, e.g., pitultary gland tissue or from mlcroorganisms trans-formed by recombinant genetics to produce a somatotropin having thesame amino acid sequence as the naturally-occurring form of somato-tropin.
The mammalian somatotropins are very similar in amino acid ~0'i3'~8 -s-sequence and physical structure. Although the processes described in the Examples are directed toward bSt, the processes are sgually applicable to any animal, e.g., mammalian somatotropin having the requisite asparagine residue available for replacement particularly wherein similar liquid processing and storage problems are en-countered.
The high relative potency of the bSt analogs of the present invention is readily determlned using hypophysectomized rats. Evans, H.M. and Long J.A., Anat. Rec. 21:61, 1921. Relative increases in 1.0 total body weight are recorded using pituitary bSt, recombinant bSt (rbSt) and various bSt analogs of the invention.
Site-Directed Mutagenesis: Several techniques for site-directed mutagenesis have been developed for introducing specific changes in a DNA sequence and may be used to produce the compounds of the instant invention (Kramer, W., et al, Nucl. Acids Res., 12, pp. 9441-56 (1984); Mandecki, W., Proc. Natl. Acad. Sci. USA, 83, pp. 7177-81 (1986); Zoller, M.J. and Smith, M., Nucl. Acids Res., 10, pp. 6487-6500 (1982); Norrander, J., et. al., Gene, 26, pp. 101-106 (1983);
Kunkel, T.A., Proc. Natl. Acad. Sci. ~SA, 82, pp. 488-92 (1985);
Schold, A., et. al., DNA, 3, pp. 469-77 (1984)). We employed the primer directed mutagenesis technique of Schold et al for five of the seven analogs produced, except that only one primer is used for the initial hybridi.zation reaction and 18 ~1 of T4 gene 32 protein is added to the extension reaction.
Colony Filter Hybridization: The screening technique of filter hybridization is based upon the ability of a single-stranded segment of DNA to locate its complementary sequence and hybrldize to form a double-stranded segment, Hanahan, D. and Meselson, M., Meth. En-zymol., 100, pp. 333-42 (1983). The therlllnl stnbility oE this binding is dependent upon the nulllber oE mntches ~nd mismatches contained within the double stranded region. The more mismatches it contains, the weaker the base-pair bi.nding and the lower the tempera-ture necessary to disrupt the DNA binding. This temperature dif-ferential is exploited during colony fi.lter hybridizati.on, Bryan, R., et. al., Microbiology (1986). By constructing a mutant oligomer which maximizes the temperature differential between the native and mutant sequence, it is possible to hybridize at a lower temperature allowing binding of the probe to matched and nearly matched sequen-0 13 ~ ~ 8 ces. Upon w~shing at elevated t~mperatures, the mismatched probe-DNA
duplex beco~es unstable and disassociates while the perfectly matched duplex remains bound. The matched duplex will then produce the darkest signaL on an autoradiogram thus forming a detection method for a colony containing the desired sequence. DNA from this colony can then be isolated and sequenced.
For filter preparation, nitrocellulose filters are overlayed onto plates and wetted. The filters and plateq are ~arked for orientation and the filters are then carefully lifted off the plates.
The master filter plates are incubated overnight at room temperature to allow re-growth of the colonies. The filters are denatured by laying them one by one onto Whatman paper soaked in 0.5 M NaOH, 1.5 M
NaCl for 10 minutes and neutralized in two successive changes of Whatman paper soaked in 1 M Tris, pH 7.4, 1.5 M NaCl, for 10 minutes each and air dried on fresh Whatman paper for 30 minutes. They are then baked for 2 hours at 80C in vacuum.
The kinase reaction to radiolabel the mutant oligonucleotide for use as a probe is as follows: 2 ~g of oligo, 2 ~1 of lOX kinase buffer, 100 ~Cl ~32-P ATP, 2 ~1 T4 kinase and 4 ~1 water are mixed and incubated for 1 hour at 37C. A 1 ml column is packed with DEAE-Sephacel in a 10 ml disposable column and equilibrated with 2-3 ml of high salt buffer (1.5M NaCl in TE) and then 2-3 ml of low salt buffer (0.2M NaCl in TE). The kinase reaction is diluted with 200 ~1 of low salt buffer and loaded directly into the column. The column is washed with 10 ml of low salt buffer until no further counts elute from the column. The probe is eluted in 4 ml of high salt buffer.
To hybridize, the filters are placed in a crystallization dish and batch pre-hybridized in 5X Denhardts (1% BSA, 1% Ficoll and 1%
PVP), 5X SSC (0.75 M NAC1, 0.075 M sodiwn cltrate) and 0,1~ SDS for 1 hour at 40C. The hybridiz~tlon solution is ch~lnged ~nd the probo is added. The dish is covered and the hybridizstion done overnight with gentle agitation. The filters are then rinsed wlth several changes of 5X SSC, 0.1% SDS. The filters sit in this solution while the water bath and wash solution (5X SSC, 0.1% SDS) is heated up to washlng temperature (46C). The filters are transferred one by one to a fresh crystallization dish and washed 3 x 20 minutes, changing dishes after each wash. They are then air dried on Whatman paper, wrapped in Saran wrap and exposed as necessary.
;~Q~rJ~t38 Vector DNA Preparatlon: GNA for sequencin~ is obtained accord-ing to the method of L. Agellon and T. Chen, Gene Anal. Techn., 3, pp. 86-89 (1985) except that only one combined phenol/chloroform extraction ls performed and the DNA is not spin-dialy~ed through a Sephadex G-50 column.
Sequencing: Double-stranded sequencing is performed accordln~
to the following protocol: 3 ~1 2N NaOH, 2 mM EDTA is added to 12 ~1 of DNA (2 ~g) and incubated for 15 minutes. 6 ~1 3 M NaOAc, 1 ~1 primer and 100 ~1 95~ ethanol are added and the DNA precipitated on dry ice for 20-30 minuees~ The pellet is collected, washed and vacuum dried. It Ls dissolved in 13 ~1 water and 4 ~1 RT buffer (0.3 M Tris-HCl, pH 8.3, 0.375 M NaCl, 37.5 mM MgC12, 2.5 mM DTT), 2 ~1 ~32P dCTP and 1 ~1 reverse transcriptase are added. 4 ~1 of this mi~
is pipetted into 4 eppendorf tubes, each contalning 1 ~1 of G mix, A
mix, T mix or C mix. The tubes are incubated for 10 minutes at 42~C.
1 ~1 of chase mix (0.25 mM dNTPs) is added and they are incubated for an additlonal 5 minutes. 10 ~1 stop solution (80~ formamide, 10 mM
NaOH, 1 mM EDTA, 0.1% xylene cyanol and 0.1~ bromphenol blue~ is added, the reactions are boiled 3 minutes and 3 ~1 of each is loaded onto a sequencing gel.
Induction Protocol and SDS-PAGE Analysis: See PCT/VS 88/00328.
Example 1 A site-directed mutagenic technique for double-stranded primer extension is u.sed to introduce altered codons for serine and proline at amino acid position 99 in the rbSt cDNA m4 gene (PCT patent application PCT/US 88/00328, filed 27 January 1988 and incorporated herein by reference). In this method, the target sequence is cloned into a suitable plasmid and plasmid DNA is prepared. The plaslnid DNA
is denatured by treatment with NaOH whi~h causes "nicks" in the DNA
molecule deoxyribose-phosph~lte baGkbon~. 'rhis relax~s the DNA and permits an oli~omer containing tho deslred sequence chan~es to hybridize to the plasmld sequence containing the position 99 residue of bSt. The 3' end of the oligomer generates a prime.r Eor the DNA
polymerase activity of the reverse transcriptase which extends the primer, synthesizes a new DNA strand containing the mutagenic oli~omer and displaces the normal complementary strand. The exten-sion reaction increases the probability of the incorporation of the oligomer-directed change. The DNA is transformed into competent ;~o~
cells and the resultant colonies are screened by colony filter hybridization. Plasmid DNA ls isolsted and sequenced from positive candidates.
The oligomers used to construct the position 99 serine and proline changes in the rbSt m4 gene are produced by techniques previously described (PCT/US 88/00328), An oligonucleotide so produced and designated GST-88 (Chart 3) contains the change on the DNA sequence asparagine AAC to serine TCT and another designated CST-89 (Chart 3) contains the asparagine AAC to proline CCG change. They are both designed with a Tm of 53C thus allowing for hybridization at 40C and stringent washing at 46C as set forth above.
In parallel experiments the serine and proline oligomers are hybridized to the pBR322 derived vector pTrp-BStm4, This vector contains the trp promoter and the m4 cDNA for rbSt (PCT/US 88/00328), After primer extension, the DNA is used to transform competent cells of MC1000 (available in the Experiments with Gene Fusion Strain Kit, Cold Spring Harbor Laboratory, Cold Spring Harbor, New York). The transformed cells are plated to give 100-200 colonies on ten plates.
The colonies are then transferred onto nitrocellulose, The cells are lysed and their DNA affixed to the filter, Radiolabeled oligomer probes are prepared from CST-88 and CST-89 by the oligomers with kinase and 32P-ATP. Details of the colony filter hybridization probing are set forth above, Six candidates gave a very strong positive signal on the autoradiogram for the serine mutagenesis, Plasmid DNA was isolated for each candiclate and sequenced, One of the candidates was found to contain the serine change, The mutated gene contained therein is designated m4-99ser. For the proline mutagenesis, six positive candidates were analyz,ed by DNA sequencing and two were found to contain the desired change. These mutated genes ~ro clcsignflted m4-99pro.
The m4~99ser and m4-99pro genes are excised from the parental vector as an EcoRI-HindIII fragment and cloned into the EcoRI-HindIII
restriction sites of the pURA-m4 vector (PCT/US 88/00328). Chart 2 shows the cloning of the m4-99ser gene into the pURA-m4 vector, The identiccal construction is carried Otlt for the m4-99pro gene. Upon sequence confirmation of the clonings, the vectors are designated pURA-99Ser and pURA-99Pro. These vectors are transformed into 3'i8 fermentation expression strain BST-lC (P~T/~S 88/00328).
Transformed cells from each of the clonings are induced and samples analyzed by SDS-PAGE to assess the ability of the cells to express the modified rbSt genes under non-optimized conditions Results of SDS-PAGE analy~is showed that pURA-99Ser produced rbSt in three indlvidual inductions at 13.8%, 14.6~ and 26.4% of total cellular protein. Results of SDS-PAGE analysis showed pURA-99Pro in four separate inductions expressed rbSt at 28.2%, 29.6~, 34.0~ and 41.9% of total cellular protein.
Because of poor mutagenic efficiency, the mutant oligomer must be constructed so that there is at least a 5~C temperature difference between its Tm and that o~ the native sequence. Witho~lt this difference, effective screening of the candidates cannot be ac-complished.
Example 2 Following the techniques of Example 1, but substituting the appropriate oligomers encoding the desired amino acids (C-ST 90 and C-ST 91, Chart 3), bSt analogs having aspartic acid and glutamic acid at position 99 were also constructed.
Example 3 Analogs having two amino acids substituted in place of the position 99 asparagine (Ser-Ser and Ser-Asp) were constructed by fol-lowing the site~ directed protocol of Kramer et al, Nucl. Acids Res., 12, p. 9441-56 (1984) as described in the "Site Directed Mutagenesis Kit", commercially available from Boehringer Mannheim Biochemicals, P0 Box 50816, Indianapolis, IN 46250 (see also, Kramer, W. and H-J
Fritz, Meth. Enz., 154, pp. 350-67 (1987)). The procedure requires cloning the DNA sequence which is to be modified into the M13mp9 vector. This is done by digesti.ng vector pURA-m4 (PCT/US 88/00328) with the restriction enzymes EcoRI arld BamtlI and Lsol1~1n~ 1 DNA
fragment approximately 870 bp ln .s i.z~ . 'I'his Eragment con~ains tlle E .
coli tryptophan (trp) promoter, ttle trpL rlbosome blnding site an~
the entire bSt gene sequence. This fragment is cloned into the EcoRI
and BamHI restriction sites of the M13mp9 vector using known techni-ques (Maniatis et al, Molecular Cloning: A Laboratory Manu~l, ColdSpring Harbor Publication, Cold Spring Harbor, New York; J. Messing, Meth. En~ym., 101, pp. 20-98 (1983)). Single stranded DNA is isolated using the derived vector M13mp9-m4 (Messing, supra) and used 3 rj 8 in the mutagenesis procedure as previously descrlbed. Cloning of these analogs into the pURA expression vector was done as described in Exa~.ple 1, in which ~he double-stranded DNA of the M13 vector, supra, is substituted for the pBR322 vector Example 4 A position 99 analog having glycine substituted for asparagine was also constructed using the techniques described in Example 1.
The mutagenesis oligonucleotide used is designated C-ST84 (Chart 3).
It encodes the change to glycine.
Example 5 Activity of various position 99 analogs was demonstrated. The parameter measured was to estimate differences in 3.5~ fat corrected milk yield (FCM) of lactating dairy cows in~ected intramuscularly with native rbSt, the glycine-99 (Gly-99) rbSt of Example 4, the serine-99 (Ser-99) rbSt of Example 1 and the aspartic acid-99 (Asp-99) rbSt of Example 2. Holstein cows (45) were ranked from high to low milk yield based on milk yield on days 3 and 2 prior to initia-tion of rbSt injections. The cows were assigned randomly in repli-cates, based upon milk yield, to 9 experimental groups: no injection (Control), 5 mg and 20 mg Gly-99 rbSt daily, 5 mg and 20 mg Ser-99 rbSt daily, 5 mg and 20 mg Asp-99 rbSt daily, and 5 mg and 20 mg native rbSt daily. Cows were in;ected imtramuscularly in the semitendinosus muscle once daily for 21 days. Twice daily milk weights were recorded for three days prior to initiation of injec-tion, during the 21 days of injections, and for fi.ve days after the last in~ection. Concentration of rbSt was expected to be 10 mg/ml.
The concentration of residual post-injection rbSt solutions, measured by HPLC, averaged 11.5 for native rbSt, 12.1 for Asp-99 rbSt, 11.6 for Gly-99 rbSt, and 11.6 for Ser-99 rbSt. The area percent was greater than 99~ normal rbSt for Gly-99 rbSt (by "norm~l rbSt" is meant the amino Mcid s~cluenco Qncoded by ~ particular gene, i.e., no degrad~tion products, otc.), for Ser-99 rbSt, and for Asp-99 rbSt, but averaged 90.5 normal rbSt for native rbSt. Native rbSt averaged 2~ early-early eluting rbSt and 7.6~ early eluting rbSt.
Statistical analyses of the FCM among experimental groups were based on average FCM for days 1 to 21 of in~ections using the three days prior to initiation of injections as the covariate. Average daily FCM (kg/day) was not statistically significantly different for either form of rbSt (Y<.12) or dose X form o~ rbSt interaction (P<.90). However, since the statistical signlficance was P<.12 for form of rbSt, an attempt was made to gain additional information on the relative potency among the forms of rbSt. Based on comparisons among the four forms of rbSt, there was a suggestion (P<.05) that FCM
of cows injected with Ser-99 rbSt was grea~er than FCM for cows injected with eLther Gly-99 rbSt or native rbst. There was no suggestion of a difference in FCM of cows injected with Ser-99 rbSt compared to cows injected with Asp-99 rbSt or among cows injected with Gly-99 rbSt, Asp-99 rbSt, and native rbSt. FCM of cows adminis-tered 20 mg rbSt was statist;cally significantly greater than cows administered 5 mg.
Experimental Mean FCM Relative to Changea Percentage 15 GroupDays of Injection(kg/day) Change for Days pre durlng post duringa postb Control 27.6 26.1 26.1 -1.5 -5.4 0 Native 5 mg 28.2 28.0 26.8 -0.2 -0.7 -4.3 Native 20 mg 26.6 30.2 26.0 3.6 13.5 -13.5 Asp-99 5 mg 28.1 29.2 29.2 1.1 3.9 0 Asp-99 20 mg 24.5 29.0 27.0 4.5 18.4 -6.9 Gly-99 5 mg 29.3 29.4 17.2 0.1 0.3 -7.5 Gly-99 20 mg 26.4 29.8 28.6 3.4 12.9 -4.2 Ser-99 5 mg 28.8 31.0 30.4 2.2 7.6 -1.9 Ser-99 20 mg 28.9 33.5 31.6 4.6 15.9 -5.7 aDays 1 to 21 o injectlon relatlve to days 1 to 3 pre-in~oction.
bDays 1 to 5 post-ln~ectl.oll r~lntlvo to dsys 1 to 21 of lnJection.
F.x~mple 6 Activity oE other position 99 analogs was demonstrated in a separate study from that reported in Example 5. Again, the param~ter measured was to estimate differences in 3.5% fat corrected milk yield (FCM) of lactatlng dairy cows injected intramuscularly with native rbSt (clinical rbSt) that has asparagine at position 99, rbSt with proline substituted for asparaglne at posltion 99 (Pro-99 rbSt), and ~r~r~
rbSt with glutamic acid substituted for asparagine at position 99 (Glu-99 rbSt). Holstein cows ~35) were ranked from high to low milk yield based on milk yield on days 3 and 2 prior to initlation of rbSt injections. The cows were assigned randomly in replicates, based upon mllk yield, to 7 experimental groups: no injection (Control), 5 mg and 15 mg Pro-99 rbSt daily, 5 mg and 15 mg Glu-99 rbSt daily, and 5 mg and 15 mg native rbSt daily. Cows were injected imtramuscularly in the semitendinosus muscle once daily for 7 days. Twice daily m~lk weights were recorded for three days prior to initiation of injec-tion, during the 7 days of injections, and for five days after thelast injection.
The dose averaged 5.04 mg, 4.88 mg, and 5.03 mg for cows assigned to receive the 5 mg dose of Pro-99, Glu-99, and native rbSt respectively. Cows assigned to receive 15 mg rbSt received 15.12 mg, 14.64 mg, and 15.10 mg rbSt for cows of the Pro-99, Glu-99, and native rbSt respectively. The percentage of early-early eluting rbSt, early eluting rbSt, oxidized rbSt, and post-oxidized rbSt appeared to be similar for native rbSt, Glu-99 rbSt, and Pro-99 rbSt.
Statistical ana].yses of the FCM among Experimental Groups were based upon average FCM for days 1 to 7 of injections using the three days prior to initiation of injections as the covariate. The FCM for cows of the native rbSt, Pro-99 rbSt, and Glu-99 rbSt groups was 28.7, 28.8, and 28.8 (P .95). Therefore there was no suggestion of a difference of FCM for cows receiving nati~e rbSt, cows receiving rbSt with glutamic acid substituted for asparagine at position 99, and cows receiving rbSt with proline substituted for asparagine at position 99. FCM was significantly greater for cows of the 15 mg rbSt group than for cows of the 5 mg rbSt group. Upon cessation of rbSt in~ections, FCM of rbSt previously inJocted cows d~creased at similar rates during the 5 days after cessAtion of rbSt in~ections.
Rxample 7 Samples of rbSt and rbSt position 99 analogs were examined for relative potency using the hypophysectomized rat growth bioassay.
Two hundred hypophysectomized fema].e Sprague Dawley rats weighing between 75 and 150 grams were used in each experiment. They were fed pelleted Purina Rat Chow ad libitum and watered with deionized and rechlorinated water. Room conditions were set at a temperature of 80 F and relative humidity of 50%. Air exchange was approximately ;~0~;3'~
20 exchanges per hour and the photoperiod was 12 hours light nnd 12 hours dark, with the light cycle commencing about 6:00 a.m.
The rats were monitored for a 12-day prelimlnary period to allow for adaptation to environmental and feeding conditions. Body weights were obtained on four occasions between days one and twelve. Rats that showed weight losses of one gram per day or less or weight gains of 2 grams per day or less during the preliminary period were selected for inJeCtion with rbSt. The rats were ranked according to ascending magnitude of average daily galn (ADG), and seven blocks of 25 rats were created. Treatments within each block were randomly assigned.
rbSe treatments lasted 10 days. During this time, test co~-pounds were injected twice daily for nine days, and body weights were monitored using a Mettler Model 3600 top loading balance equipped with lab-Pac programming which determines the weight of the animals while taking into account their movements.
Stock solutions of rbSt at 2 mg/ml were prepared in a buffer of 0.03 M sodium bicarbonate and 0.15 M NaCl at pH g.5. To facilitate suspension of rbSt, the ].yophilized preparations were first dissolved 20 in this buffer at pH 10.8, then the pH was adjusted to 9.5 using 2 N
HCl and brought to final volume using the stock buffer at pH 9.5 and filtered if necessary.
The stock solutions were diluted using stock bufEer (pH 9.5) to solutions of 37.5, 75, 150, and 300 mg of protein/ml. The rats were injected subcutaneously twice daily with 100 ~1 of the respective solutions, and controls received 100 ~1 of buffer. The experiment lasted 10 days with average daily weight gain monitored.
A statistical analysis of the relative potency for the various test samples of rbSt was as follows: native rbSt with asparagine at position 99 served as an analytical st~ndard and wns nssigned relative potency vAlue o~ 1.00. 'I'hi.s sampl.c had a potency of 1.15 relative to A snmple of pltuitnry-tlerlved bovinc somatotropin. The rbSt analogs in which aspartlc ncid, glutamic acid, glycine, proline, serine, and serine-serine were substituted for the asparagine at 35 position 99, had relative potencies (respecti.vely) of 2.30, 3.00, 2.96, 2.50, 3.06, and 3.03 relative to rbSt control. These values are significant at the 95~ confldence level.
;~C~ ~3'~
Example 8 The aqueous stabilities of three of the rbSt position 99 analogs, having glycine, serine, and aspartic acid substituted for asparagine, were compared wlth that of native (asparagine at 99) rbSt under two sets of incubation conditions. The first set of incuba-tions was carried out in 50 mM sodium carbonate, pH 10.0 at ambient temperature (protein concentration 20 mg/ml) to simulate conditions similar to those encountered during the isolation and formulation of rbSt. The second set of incubations was carried out in a pH 7.4 Ringer's solution at 37C (protein concentration 5 mg/ml) to simulate exposure to physiological conditions. All incubation samples were prepared aseptically. Samples were removed from the incubations over a three week period and stored at -20C prior to analysis by iso-electric focusing, SDS-PAGE, and reversed phase HPLC.
The glycine 99 and serine 99 rbSt analogs had IEF patterns that were virtually indistinguishable from native rbSt prior to incubation while the IEF pattern of native asparagine 99 rbSt was shifted approximately 1.2 pH units lower due to the introduction of the negative charge at position 99. The major difference noted between the IEF patterns of incubated samples of native rbSt and the position 99 analogs was the rate at which more acidic rbSt species were formed. The IEF pattern of native rbSt degraded into more acidic rbSt spe~ies at a faster rate under both sets of incubation condi-tions than did the IEF patterns of the position 99 analogs. One additional difference between the IEF patterns of native rbSt and the analogs was the presence in incubated native rbSt samples of IEF
bands that have been associated with a chain cleavage between residues 99 and 100 of the rbSt molecule. These bands were not observed in the IEF patterns of the position 99 analog~.
~en analyzed under non-reducln~ conditlons, the SDS PACE
behavior of incubat~d samples of the posLtion 99 analog~ was identi-cal to that of native rbSt. When examined under reducing conditions, however, the major rbSt fragment formed during the incubation of native rbSt was found to be absent in the position 99 analogs.
Replacement of the asparagine residue at position 99 with either glycine, serine, or aspartic acid therefore eliminated the peptide bond cleavage between residues 99 and 100. The two peptides formed as a result of this cleavage in native rbSt are normally held - 1 s -covalently intact by the disulfide bond between cysteine residues 53 and 164, thus the difference between the reduced and non-reduced s~mples.
Reversed phase HPLC was used to measure the amount of isoaspar-tate formation and chain cleavage which occurred at position 99 of the rbSt molecule since these species elute earlier upon reversed phase ~IPLC than native rbSt. rbSt which contained a chain cleavage between positions 99 and 100 of the rbSt molecule accounted for 8.5 area percent of native rbSt at the conelusion of the pH 10.0 incuba-tion, and for 11.1 area pereent of native rbSt at the conelusion ofthe pH 7.4 incubation. By comparison, the amount of the rbSt analogs which eluted in this position was less than 0.5 area percent. rbSt which eluted in the position of isoaspartic acid 99 rbSt accounted for 35.8 area percent of native rbSt at the conclusion of the pH 10.0 incubation, and for 49.9 area percent of native rbSt at the con-clusion of the pH 7.4 incubation. Of the position 99 rbSt analogs, aspartic acid 99 rbSt showed the greatest formation of rbSt which eluted in this position: 3.8 area percent at the conclusion of the p~I 10.0 incubation and 13.9 area percent at the conclusion of the pH
7.4 incubation.
Therefore, the position 99 analogs of the instant invention show superior aqueous stability relative to native asparagine 99 rbSt.
Example 9 Following the teachings of the preceding examples with ap-propriate modifications, similar analogs to porcine, human, ovine,horse, rat, monkey and avian somatotropins may also be produced by replacing the asparagine residues at position 99 (S.S. Abdel-Meguid, et al, Proc. Natl. Aead. Sci.. USA, 84, pp. 6434-37 (1987). Because of the close sequence homology botween mclmmall~ oln~Itotropins in this region of the molec-I].e, tIle a~IpclrclgLlle residue corre.sponding to bSt asparagine 99 is likely tho third residue in a ~-turn in eaeh of these other somatotropins thus leading to isoaspartic acid formakion and chain cleavage as with bSt. If this is Eound to be the case for other somatotropins by analysis of the products as set forth above, substituting an appropriate amino aeid for the asparagine 99 would obviate the isoaspartate formation and chain cleavage.
Administration of the bSt analogs into dairy cattle is according to known methods using any route effective to deliver the required 2Q~ 3 ~
dosage to the animal's circulatory system. Modes of administration include oral, intramuscular in~ections, subcutaneous in3ectlons and the use of timed-release implants. The preferred mode of administra-tion is by subcutaneous in~ection using a timed-release implant.
Appropriate vehicles for injections include physiologically com-patible buffers such as sodium bicarbonate, sodi~m phosphate, or ammonium phosphate solutions. Timed-release implants are known in the art, e.g., U.S. patent 4,333,919.
The effective dosage range is from 1.0 to 200 milligrams per animal per day. The greater the amount of bSt given, the greater the resulting increase in growth, lactation or numbers of mammary parenchymal cells. Most preferably, the dosage range is from 5 to 50 milligrams per day.
Mammalian growth hormones are very similar in their amino acid sequences and hormones originating from one animal source can enhance the growth of other unrelated species of animals. For purposes of increasing growth rate of animals, the analogs of the present invention can be used to produce increased growth in the same animal species in which native bSt has been shown to have growth-related bioactivity such as bovines, sheep, rats, salmon and chickens. The preferred animals are bovine used for beef cattle such as bulls, heifers or steers.
Beef cattle are slaughtered ~ust prior to reaching full maturity and size. The bSt analogs of the instant invention can be used to produce increased growth rates in beef cattle by administration any time between weaning until slaughter. The bSt are administered to beef cattle for a minimum of 30 days and for a maximum of 450 days depending upon desired time of slaughter. Animals used for veal are typically slaughtered at approximately 6 months of age and 10 to 30 mg/day of the bSt Dnalog is admini~tered up until the n~o of slaugh-ter to effectuate desired lncreasos in growth rate.
For purposes of increasing lactstion in bovines, particularly dairy cows, the bSt analog is administered between 30 and 90 days postpartum and continued for up to 300 days. The bSt analog will also increase lactation in other commercial milk-producing animals such as goats and sheep.
.
2~ 3'~8 CHART 1. Amino Acid Sequence Of Bovine Somatotropin ala phe pro ala met ser leu ser gly leu phe ala asn ala val leu arg ala gln his leu his gln leu ala ala asp thr phe lys glu phe glu arg thr tyr ile pro glu gly gln arg tyr ser ile gln asn thr gln val ala phe cys phe ser glu thr ile pro ala pro thr gly lys asn glu ala gln gln lys ser asp leu glu leu leu arg ile ser leu leu leu ile gln ser trp leu gly pro leu 25 gln phe leu ser arg val phe thr asn ser leu val phe gly thr ser asp arg val tyr glu lys leu lys asp leu glu glu gly ile leu ala leu met arg glu leu glu asp gly thr pro arg ala gly gln ile leu lys gln thr tyr asp lys phe asp thr asn met arg ser asp asp ala leu leu lys asn tyr gly leu leu ser cys phe arg ly9 asp leu his lys thr glu thr tyr lou srg v~l m~t lys cys arg arg phe gly glu ala ser cys ala phe CH~RT 2. Clonlng of the m4-99ser gene lnto the pURA Vector 1) A plasmid contalning the m4-99ser gene ls digested with EcoRI and HindIII to produce Fragment 1.
5EcoRI HindIII
BBBBBBBBBBBBBBBBB ¦ ~--------------ori Ampr Fragment 1 EcoRI HindIII
BBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBB
2) Plasmid pURA-m4 is digested with EcoRI and HindIII to produce Fragment 2.
EcoRI HindIII
* I ,,__. l l l l I , cop cop rep ori ori Ampr Fragment 2 HindIII EcoRI
cop cop rep ori ori Ampr 3) Fragments 1 and 2 are then lignted togeth~r to protl~lc~
0 plnsmid pURA-99ser.
HindIII EcoRI
* ---~ I *
BBBBBBBBBBBBBBB
cop cop rep ori ori Ampr B ~ bSt m4-99ser gene ~05;~
CHART 3. Ollgonucleotides Used for Constructing rbSt Analogs C-ST 84 (gly) 5'-GTCTTCACCGGTAGCTTGGTG
C-ST 88 (ser) 5'-GTCTTCACCTCTAGCTTGGTG
C-ST 89 (pro) 5'-GTCTTCACCCCGAGCTTGGTG
C^ST 90 (asp) 5'-GAGTCTTCACTGATAGCTTGGTG
C-ST 91 (glu) 5'-GAGTCTTCACTGAAAGCTTGGTG
JM 23 (ser-ser) 5'- AGCAGAGTCTTCACCTCTTCCTCTTTGGTGTTTGGCACC
JM 57 (ser-asp) 5'-TCAGCAGAGTCTTCACCTCTGACTCCTTGGTGTTTGGCACCTCGG
Claims (17)
1. An animal somatotropin in which the asparagine residue cor-responding to residue 99 of the native somatotropin as exemplified in Chart 1, is replaced with at least one different amino acid selected from the group consisting of:
(a) proline;
(b) serine;
(c) glycine;
(d) serine-serine; or (e) serine-aspartic acid.
(a) proline;
(b) serine;
(c) glycine;
(d) serine-serine; or (e) serine-aspartic acid.
2. A mammalian somatotropin according to claim 1 wherein the asparagine is replaced with proline.
3. A mammalian somatotropin according to claim 1 wherein the asparagine is replaced with serine.
4. A mammalian somatotropin according to claim 1 wherein the asparagine is replaced with glycine.
5. A mammalian somatotropin according to claim 1 wherein the asparagine is replaced with serine-serine.
6. A mammalian somatotropin according to claim 1 wherein the asparagine is replaced with serine-aspartic acid.
7. An animal somatotropin according to claim 1, selected from the group consisting of bovine, porcine, fish, ovine, horse, rat, monkey, and human somatotropins.
8. An animal somatotropin according to claim 1, which is bovine somatotropin.
9. An animal somatotropin according to claim 1, which is bovine somatotropin.
10. An animal somatotropin according to claim 3, which is bovine somatotropin.
11. An animal somatotropin according to claim 4, which is bovine somatotropin.
12. An animal somatotropin according to claim 5, which is bovine somatotropin.
13. An animal somatotropin according to claim 6, which is bovine somatotropin.
14. An animal somatotropin according to claim 7, which is bovine somatotropin.
15. A method for enhancing the growth of an animal which comprises administering to the animal an effective amount of a somatotropin of claim 1.
16. The method of claim 15 wherein the animal is a bovine.
17. A method for increasing milk production in a cow comprising administering to the cow an effective amount of an animal somato-tropin of claim 1.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US29910789A | 1989-01-19 | 1989-01-19 | |
| US07/299,107 | 1989-01-19 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2005358A1 true CA2005358A1 (en) | 1990-07-19 |
Family
ID=23153338
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002005358A Abandoned CA2005358A1 (en) | 1989-01-19 | 1989-12-13 | Somatotropin analogs |
Country Status (7)
| Country | Link |
|---|---|
| EP (1) | EP0454730A1 (en) |
| JP (1) | JPH04502762A (en) |
| KR (1) | KR910700264A (en) |
| AU (1) | AU634517B2 (en) |
| CA (1) | CA2005358A1 (en) |
| DK (1) | DK136991A (en) |
| WO (1) | WO1990008164A1 (en) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0355460B1 (en) * | 1988-08-24 | 2000-12-27 | American Cyanamid Company | Stabilization of somatotropins by modification of cysteine residues utilizing site directed mutagenesis or chemical derivatization |
| ZA936811B (en) * | 1992-10-28 | 1995-03-15 | Upjohn Co | Somatotropin modifications |
| US8008252B2 (en) | 2001-10-10 | 2011-08-30 | Novo Nordisk A/S | Factor VII: remodeling and glycoconjugation of Factor VII |
| US7173003B2 (en) | 2001-10-10 | 2007-02-06 | Neose Technologies, Inc. | Granulocyte colony stimulating factor: remodeling and glycoconjugation of G-CSF |
| US7696163B2 (en) | 2001-10-10 | 2010-04-13 | Novo Nordisk A/S | Erythropoietin: remodeling and glycoconjugation of erythropoietin |
| US7795210B2 (en) | 2001-10-10 | 2010-09-14 | Novo Nordisk A/S | Protein remodeling methods and proteins/peptides produced by the methods |
| US7214660B2 (en) | 2001-10-10 | 2007-05-08 | Neose Technologies, Inc. | Erythropoietin: remodeling and glycoconjugation of erythropoietin |
| JP2006523211A (en) | 2003-03-14 | 2006-10-12 | ネオス テクノロジーズ インコーポレイテッド | Branched water-soluble polymers and their composites |
| EP1615945B1 (en) | 2003-04-09 | 2011-09-28 | BioGeneriX AG | Glycopegylation methods and proteins/peptides produced by the methods |
| CA2524936A1 (en) | 2003-05-09 | 2004-12-02 | Neose Technologies, Inc. | Compositions and methods for the preparation of human growth hormone glycosylation mutants |
| US9005625B2 (en) | 2003-07-25 | 2015-04-14 | Novo Nordisk A/S | Antibody toxin conjugates |
| US8633157B2 (en) | 2003-11-24 | 2014-01-21 | Novo Nordisk A/S | Glycopegylated erythropoietin |
| US20080305992A1 (en) | 2003-11-24 | 2008-12-11 | Neose Technologies, Inc. | Glycopegylated erythropoietin |
| US7956032B2 (en) | 2003-12-03 | 2011-06-07 | Novo Nordisk A/S | Glycopegylated granulocyte colony stimulating factor |
| EP1765853B1 (en) | 2004-01-08 | 2015-10-28 | ratiopharm GmbH | O-linked glycosylation of G-CSF peptides |
| WO2006010143A2 (en) | 2004-07-13 | 2006-01-26 | Neose Technologies, Inc. | Branched peg remodeling and glycosylation of glucagon-like peptide-1 [glp-1] |
| US8268967B2 (en) | 2004-09-10 | 2012-09-18 | Novo Nordisk A/S | Glycopegylated interferon α |
| EP3061461A1 (en) | 2004-10-29 | 2016-08-31 | ratiopharm GmbH | Remodeling and glycopegylation of fibroblast growth factor (fgf) |
| WO2006074467A2 (en) | 2005-01-10 | 2006-07-13 | Neose Technologies, Inc. | Glycopegylated granulocyte colony stimulating factor |
| EP1871795A4 (en) | 2005-04-08 | 2010-03-31 | Biogenerix Ag | Compositions and methods for the preparation of protease resistant human growth hormone glycosylation mutants |
| WO2006127910A2 (en) | 2005-05-25 | 2006-11-30 | Neose Technologies, Inc. | Glycopegylated erythropoietin formulations |
| US20070105755A1 (en) | 2005-10-26 | 2007-05-10 | Neose Technologies, Inc. | One pot desialylation and glycopegylation of therapeutic peptides |
| US20090048440A1 (en) | 2005-11-03 | 2009-02-19 | Neose Technologies, Inc. | Nucleotide Sugar Purification Using Membranes |
| CN101516388B (en) | 2006-07-21 | 2012-10-31 | 诺和诺德公司 | Glycosylation of peptides via O-linked glycosylation sequences |
| EP2054521A4 (en) | 2006-10-03 | 2012-12-19 | Novo Nordisk As | Methods for the purification of polypeptide conjugates |
| CA2682897C (en) | 2007-04-03 | 2016-11-22 | Biogenerix Ag | Methods of treatment using glycopegylated g-csf |
| WO2008154639A2 (en) | 2007-06-12 | 2008-12-18 | Neose Technologies, Inc. | Improved process for the production of nucleotide sugars |
| US8207112B2 (en) | 2007-08-29 | 2012-06-26 | Biogenerix Ag | Liquid formulation of G-CSF conjugate |
| CN101965200B (en) | 2008-02-27 | 2013-06-19 | 诺沃-诺迪斯克有限公司 | Conjugated factor VIII molecules |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ201918A (en) * | 1981-09-18 | 1987-04-30 | Genentech Inc | N-terminal methionyl analogues of bovine growth hormone |
| EP0085036A1 (en) * | 1982-01-18 | 1983-08-03 | Monsanto Company | Method for improved bovine milk production |
| US4446235A (en) * | 1982-03-22 | 1984-05-01 | Genentech, Inc. | Method for cloning human growth hormone varient genes |
| DE3675382D1 (en) * | 1985-09-18 | 1990-12-06 | Upjohn Co | INCREASED BIOLOGICAL EFFECT OF MAMMAL SOMATOTROPINE BY SELECTIVE DEAMIDATION. |
| US5104806A (en) * | 1987-03-12 | 1992-04-14 | Amgen, Inc. | Porcine growth hormone analogs encoding dna |
-
1989
- 1989-12-11 JP JP2502084A patent/JPH04502762A/en active Pending
- 1989-12-11 EP EP90901997A patent/EP0454730A1/en not_active Withdrawn
- 1989-12-11 KR KR1019900702070A patent/KR910700264A/en not_active Application Discontinuation
- 1989-12-11 AU AU49427/90A patent/AU634517B2/en not_active Ceased
- 1989-12-11 WO PCT/US1989/005447 patent/WO1990008164A1/en not_active Application Discontinuation
- 1989-12-13 CA CA002005358A patent/CA2005358A1/en not_active Abandoned
-
1991
- 1991-07-17 DK DK136991A patent/DK136991A/en not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| DK136991D0 (en) | 1991-07-17 |
| EP0454730A1 (en) | 1991-11-06 |
| WO1990008164A1 (en) | 1990-07-26 |
| DK136991A (en) | 1991-07-17 |
| JPH04502762A (en) | 1992-05-21 |
| AU634517B2 (en) | 1993-02-25 |
| KR910700264A (en) | 1991-03-14 |
| AU4942790A (en) | 1990-08-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU634517B2 (en) | Somatotropin analogs | |
| FI113372B (en) | Method for Preparation of a LIF Polypeptide (LIF = Leukemia Inhibiting Factor) | |
| US5155214A (en) | Basic fibroblast growth factor | |
| AU620673B2 (en) | Somatotropin analogs | |
| CA1340455C (en) | Human preproinsulin-like growth factor i | |
| GB2147902A (en) | Microbially produced bgh and its use | |
| SK171492A3 (en) | Polypeptide, method of its preparation its use and pharmaceutical agent | |
| EP0111389A2 (en) | Substantially pure porcine growth hormone, DNA sequences therefor, and expression vehicles and transfected microorganisms for the production of porcine growth hormone | |
| US5464774A (en) | Bovine basic fibroblast growth factor | |
| Keshet et al. | Cloning of bovine growth hormone gene and its expression in bacteria | |
| FI81378B (en) | DNA SOM KODAR FOER EN PREKURSOR TILL HPGRF, EXPRESSIONSVEKTOR OCH FOERFARANDE FOER EXPRESSION AV EN PREKURSOR TILL HPGRF. | |
| AU639245B2 (en) | Somatotropin analogs | |
| US5631227A (en) | Somatotropin analogs | |
| US5070075A (en) | Human preproinsulin-like growth factor I | |
| EP0282319B1 (en) | Porcine growth hormone analogs | |
| EP0236452B1 (en) | Enhanced bioactivity of mammalian somatotropin through selective deamidation | |
| EP0303858A2 (en) | Cloning of dna encoding antibacterial polypeptide precursor and expression of the precursor | |
| US5663305A (en) | Somatotropin analogs | |
| EP0263206B1 (en) | Enhanced bioactivity of mammalian somatotropin through selective deamidation | |
| KR0121322B1 (en) | Recombinant dna molecules and host cells for production of leukemia inhibitory factor | |
| HU204889B (en) | Process for producing erythropoietin |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| FZDE | Dead |